Patients’ characteristics
A total of 42 patients in the CLBBB group and 168 patients in the
Non-CLBBB group were included in the study. The baseline characteristics
were listed in Table 1. QRS duration were 157.0 (122.0-200.0) ms and
90.0 (68.0-118.0) ms in the two groups, respectively (P <
0.001). All the other baseline characteristics were not significantly
different between the two groups.
Three months after the procedure, the proportion of antiarrhythmic drugs
(include I, III and IV class AADs) in the two groups was 23.8% in the
CLBBB group versus 26.8% in the Non-CLBBB group (P=0.695). The
proportion of the patients on ACEI/ARBs, statins, and β-blockers was
comparable between the two groups. During follow-up, there were no
significant differences in anticoagulation and antiplatelet medication
between the CLBBB group and the Non-CLBBB group (19.0% vs. 16.7%,
P=0.714; 7.1% vs. 2.4%, P=0.290).